Goldman Sachs and Biotech

Selected healthcare news for the capital firm - Goldman Sachs, and the healthcare topic - Biotech. We have 485 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/11/2022 Shanghai ZhenGe Biotech Raises USD 100 million Round C Led by Goldman Sachs Asset Management and Sofina SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Shanghai ZhenGe Biotech Co., Ltd. ("ZhenGe Biotech" or "the Company") announced the completion of round C financing of US $100 million, led by Goldman Sachs Asset Management and Sofina. Also investing were Novo Holdings A/S, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital and Cowin Capital.The proceeds from Round C will be used to strengthen ZhenGe Biotech's global R & D capabilities and ...
1/11/2022 Shanghai ZhenGe Biotech Raises USD 100 million Round C Led by Goldman Sachs Asset Management and Sofina This post was originally published and is credit to this siteSHANGHAI, Jan. 11, 2022 /PRNewswire/ ‚Ai Shanghai ZhenGe Biotech Co., Ltd. (‚AuZhenGe Biotech‚Au or ‚Authe Company‚Au) announced the completion of round C financing of US $100 million, led by Goldman Sachs Asset Management and Sofina. Also investing were Novo Holdings A/S, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital and Cowin Capital.The proceeds from ...
12/9/2021 The World's First $20 Trillion Drug? Below is an important message from one of our valued partners along with today's top headlinesDecember 08, 2021The World's First $20 Trillion Drug? - Ad One small biotech holds the key to a revolution in treating Alzheimer's. Jeff Bezos, Goldman Sachs & a Big Pharma giant have invested billions into this unknown biotech. Our research shows that anyone who gets in today, could turn every $1,000 into $1.1 million. Read ...
12/1/2021 Krystal Biotech Announces Pricing of $200 Million Public Globe Newswire PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the ‚AuCompany‚Au), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering ... December 3, 2021, subject to satisfaction of customary closing conditions.Goldman Sachs & Co. LLC, BofA Securities, Cowen and William Blair are acting as the book-running managers for the offering. Chardan is acting as lead ...
12/1/2021 Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) ‚Ai Krystal Biotech, Inc. (NASDAQ: KRYS) (the ‚AuCompany‚Au), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public ... December 3, 2021, subject to satisfaction of customary closing conditions.Goldman Sachs & Co. LLC, BofA Securities, Cowen and William Blair are acting as the book-running managers for the offering. Chardan is acting as lead ...
10/19/2021 Natixis Sells 978 Shares of Burning Rock Biotech Limited (NASDAQ:BNR) Natixis trimmed its holdings in Burning Rock Biotech Limited (NASDAQ:BNR) by 1.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,002 shares of ... in Burning Rock Biotech during the second quarter worth $51,122,000. Goldman Sachs Group Inc. acquired a new position in Burning Rock Biotech during the first quarter worth $18,444,000. Gilder Gagnon Howe & Co. LLC raised its ...
10/18/2021 150,539 Shares in Burning Rock Biotech Limited (NASDAQ:BNR) Acquired by Legal & General Group Plc Legal & General Group Plc acquired a new position in Burning Rock Biotech Limited (NASDAQ:BNR) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 150,539 ... Burning Rock Biotech in the 2nd quarter worth approximately $51,122,000. Goldman Sachs Group Inc. purchased a new stake in Burning Rock Biotech in the 1st quarter worth approximately $18,444,000. Gilder Gagnon Howe & Co. LLC lifted ...
10/16/2021 Krystal Biotech (NASDAQ:KRYS) Rating Lowered to Sell at Zacks Investment Research Mayfield Recorder Zacks Investment Research cut shares of Krystal Biotech (NASDAQ:KRYS) from a hold rating to a sell rating in a research note issued to investors on Wednesday, Zacks.com reports.According to Zacks, ‚AuKrystal Biotech, Inc ... in a research report on Friday, July 2nd. Finally, The Goldman Sachs Group upgraded Krystal Biotech from a neutral rating to a buy rating and upped their price objective for the stock from $73.00 to ...
10/13/2021 Krystal Biotech (NASDAQ:KRYS) Lowered to Sell at Zacks Investment Research - Transcript Daily Krystal Biotech (NASDAQ:KRYS) was downgraded by Zacks Investment Research from a ‚Auhold‚Au rating to a ‚Ausell‚Au rating in a research report issued on Wednesday, Zacks.com reports.According to Zacks, ‚AuKrystal Biotech, Inc ... alerts: Several other brokerages have also commented on KRYS. The Goldman Sachs Group raised Krystal Biotech from a ‚Auneutral‚Au rating to a ‚Aubuy‚Au rating and boosted their price objective for the stock from ...
10/9/2021 Trinity Biotech plc (NASDAQ:TRIB) Short Interest Update - Ticker Report Ticker Report Trinity Biotech plc (NASDAQ:TRIB) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totalling 279,200 shares, a drop of 14.9% from the August ... have recently made changes to their positions in the company. Goldman Sachs Group Inc. bought a new position in shares of Trinity Biotech in the 2nd quarter valued at about $32,000. Renaissance Technologies LLC grew ...
10/5/2021 450,000 Shares in Biotech Acquisition (NASDAQ:BIOT) Purchased by DG Capital Management LLC - American Banking News American Banking News DG Capital Management LLC bought a new position in shares of Biotech Acquisition (NASDAQ:BIOT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange ... shares of Biotech Acquisition during the second quarter worth $484,000. Goldman Sachs Group Inc. purchased a new stake in Biotech Acquisition in the 1st quarter valued at about $584,000. Finally, Susquehanna International Group LLP acquired ...
10/5/2021 Faang's Dominance Too Hard to Overcome as 10% Correction Looms ... energy shares rally as oil prices jumped to the highest since 2014. And yes, Covid treatment outlooks brightened after Israeli biotech company RedHill Biopharma Ltd. followed Merck & Co. in announcing promising data on an oral ... stocks since at least 1980, according to data compiled by Goldman Sachs Group Inc. and Bloomberg. .Here‚Aos just one example of how much tech drives the markets: If you exclude the Faang losses on ...
10/5/2021 Faang's Dominance Too Hard to Overcome as 10% Correction Looms ... energy shares rally as oil prices jumped to the highest since 2014. And yes, Covid treatment outlooks brightened after Israeli biotech company RedHill Biopharma Ltd. followed Merck & Co. in announcing promising data on an oral ... stocks since at least 1980, according to data compiled by Goldman Sachs Group Inc. and Bloomberg.Here‚Aos just one example of how much tech drives the markets: If you exclude the Faang losses on ...
9/28/2021 VanEck Vectors Biotech ETF (NASDAQ:BBH) Sees Large Volume Increase VanEck Vectors Biotech ETF (NASDAQ:BBH) shares saw an uptick in trading volume on Tuesday . 2,710 shares traded hands during mid-day trading, a decline of 81% from the previous session‚Aos volume of 14,358 ... VanEck Vectors Biotech ETF during the 2nd quarter worth $214,000. Goldman Sachs Group Inc. increased its stake in VanEck Vectors Biotech ETF by 72.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 119,442 ...
9/20/2021 Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) PT at $97.50 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned an average rating of ‚AuBuy‚Au from the seven ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the ... Biotech in a research note on Friday, July 2nd. The Goldman Sachs Group upgraded Krystal Biotech from a ‚Auneutral‚Au rating to a ‚Aubuy‚Au rating and increased their target price for the company from ...
9/17/2021 Cue Health to Sell 12 Million Shares in IPO ... biotech estimates that its initial public offering of common stock will be priced in range of $15 to $17 per share with a proposed maximum aggregate offering price of $244 million.Cue Health was founded in 2010 and its recent revenue growth has been driven by its offering of a rapid COVID-19 molecular diagnostic test, the Cue COVID-19 Test. Underwriters for Cue‚Aos IPO include Goldman Sachs & Co ...
9/14/2021 Goldman Sachs Group, Inc. (The) (NYSE:GS) ‚Äì Animal Capital, Alongside Partner Josh Richards, Spurs Thomas Tull's Colossal Stake ... lead a seed round in Colossal, a bioscience and genetics company co-founded by the world-renowned geneticist and serial biotech entrepreneur George Church, Ph.D., and Ben Lamm. What Happened: Colossal, a firm looking to ... development executive for WarnerMedia and previously an investment banker at Goldman Sachs Group Inc (NYSE: GS), added: ‚AuThe Animal Capital team is thrilled to be one of the first and biggest investors in Colossal. Ben ...
9/10/2021 Initial public offerings scheduled to debut next week ... Goldman Sachs/JP Morgan. Proposed Nasdaq symbol DH. Business: Provides a healthcare intelligence platform for go-to-market sales strategies.DICE Therapeutics - San Francisco, 10 million shares, priced $15-$17, managed by BofA Securities/SVB Leerink. Proposed Nasdaq symbol DICE. Business: Phase 1-ready biotech developing oral small molecule therapies for immunologic.Dutch Bros - Grants Pass, Oregon, 21.1 million shares, priced $18-$20, managed by BofA Securities/JP Morgan. Proposed ...
9/10/2021 Initial public offerings scheduled to debut next week ... Goldman Sachs/JP Morgan. Proposed Nasdaq symbol DH. Business: Provides a healthcare intelligence platform for go-to-market sales strategies.DICE Therapeutics - San Francisco, 10 million shares, priced $15-$17, managed by BofA Securities/SVB Leerink. Proposed Nasdaq symbol DICE. Business: Phase 1-ready biotech developing oral small molecule therapies for immunologic.Dutch Bros - Grants Pass, Oregon, 21.1 million shares, priced $18-$20, managed by BofA Securities/JP Morgan. Proposed ...
9/10/2021 Maravai LifeSciences Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders Globe Newswire ... NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of a public offering of 20,000,000 shares of Maravai ... of shares by the selling stockholders.Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel ...
9/10/2021 Maravai LifeSciences Announces Pricing of Secondary ... Ai Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of a public offering of 20,000,000 shares of Maravai ... of shares by the selling stockholders. Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel ...
9/10/2021 Initial public offerings scheduled to debut next week SFGate ... Goldman Sachs/JP Morgan. Proposed Nasdaq symbol DH. Business: Provides a healthcare intelligence platform for go-to-market sales strategies. DICE Therapeutics - San Francisco, 10 million shares, priced $15-$17, managed by BofA Securities/SVB Leerink. Proposed Nasdaq symbol DICE. Business: Phase 1-ready biotech developing oral small molecule therapies for immunologic. Dutch Bros - Grants Pass, Oregon, 21.1 million shares, priced $18-$20, managed by BofA Securities/JP Morgan. Proposed ...
9/10/2021 Initial public offerings scheduled to debut next week ... Goldman Sachs/JP Morgan. Proposed Nasdaq symbol DH. Business: Provides a healthcare intelligence platform for go-to-market sales strategies.DICE Therapeutics - San Francisco, 10 million shares, priced $15-$17, managed by BofA Securities/SVB Leerink. Proposed Nasdaq symbol DICE. Business: Phase 1-ready biotech developing oral small molecule therapies for immunologic.Dutch Bros - Grants Pass, Oregon, 21.1 million shares, priced $18-$20, managed by BofA Securities/JP Morgan. Proposed ...
9/10/2021 Initial public offerings scheduled to debut next week ... Goldman Sachs/JP Morgan. Proposed Nasdaq symbol DH. Business: Provides a healthcare intelligence platform for go-to-market sales strategies.DICE Therapeutics - San Francisco, 10 million shares, priced $15-$17, managed by BofA Securities/SVB Leerink. Proposed Nasdaq symbol DICE. Business: Phase 1-ready biotech developing oral small molecule therapies for immunologic.Dutch Bros - Grants Pass, Oregon, 21.1 million shares, priced $18-$20, managed by BofA Securities/JP Morgan. Proposed ...
9/8/2021 Trinity Biotech (TRIB) to Release Quarterly Earnings on Thursday Trinity Biotech (NASDAQ:TRIB) is scheduled to issue its quarterly earnings data before the market opens on Thursday, September 9th. Individual that wish to register for the company‚Aos earnings conference call can do so ... investor recently bought a new position in Trinity Biotech stock. Goldman Sachs Group Inc. bought a new stake in Trinity Biotech plc (NASDAQ:TRIB) during the second quarter, according to the company in its most ...